Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs iShares MSCI South Korea ETF (EWY) Price & Performance

Ginkgo Bioworks Holdings IncTrade
iShares MSCI South Korea ETFTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs iShares MSCI South Korea ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.42 (market cap $505.73M), while iShares MSCI South Korea ETF trades at $175.05. The key difference: iShares MSCI South Korea ETF is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.

DNAEWY
Market Cap
$505.73M
Sector
HealthBroad Market / Factor
52-Week High
$16.14$219.20
52-Week Low
$5.48$71.22
Enterprise Value
$607.68M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.

iShares MSCI South Korea ETF

EWY trades at $175.21, up 7.41% over the past 24 hours, showing strong momentum amid volatile South Korean market conditions. The ETF exhibits mixed technical signals with bullish moving averages but neutral oscillators, while support and resistance levels indicate potential consolidation between $166 and $172. Recent news highlights significant volatility in South Korean equities driven by AI and semiconductor sector turbulence, with foreign investors rotating capital away from Asian markets.

The outlook remains cautious as EWY faces headwinds from concentrated exposure to South Korea's volatile semiconductor sector, though government support initiatives and Goldman Sachs' bullish 90% upside projection offer potential catalysts. Key risks include continued foreign capital outflows, leveraged ETF speculation concerns, and dependence on AI-driven market swings that have caused recent sharp declines in major holdings like Samsung and SK Hynix.

Returns comparison

Trailing returns across standard periods

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA

About iShares MSCI South Korea ETF

EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.

Read more on EWY